Cortech gets pay off coming and going

Cortech Inc. has reclaimed some coveted programs from R&D partner Marion Merrell Dow, while at the same time gaining expanded financial support for the remaining projects.

Cortech said MMD has expanded development of CRTQ's lead neutrophil elastase inhibitor, CE-1037, to include aerosolized versions of the compound for two new indications: cystic fibrosis and congenital emphysema. CRTQ, which will manage preclinical and clinical development for the added indications, already is in preclinical development of an injectable version of CE-1037 for adult respiratory distress syndrome (ARDS). ...